Zacks Small Cap Research – ARWR: SHASTA-3 and SHASTA-4 Data Presented at ESC 2026
By David Bautz, PhD NASDAQ: ARWR READ THE FULL ARWR RESEARCH REPORT Business Update SHASTA-3 and SHASTA-4 Data Presented at ESC 2026 On August 30, 2026, Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) announced the presentation of results from the SHASTA-3 and SHASTA-4 trials of plozasiran in patients with severe hypertriglyceridemia (sHTG) at the European Society of Cardiology (ESC) 2026 Meeting. Highlights








